A veterinary marbofloxacin compound gel ear drops and its preparation method and application
Through the combination of mapofloxacin, ketoconazole, triamcinolide, and permethrin and acid-base neutralization methods, the problems of single dosage forms and poor stability of existing products are solved, and efficient and stable real solution ear drops are formed. , significantly improve the treatment effect and safety of pet otitis exterinary .
Patent Information
- Application Number
- CN202411139398.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-20
AI Technical Summary
The existing pet otitis externa treatment products have single dosage forms, poor stability, and difficult to effectively cover the ear canal. The market share of domestic products is low and it depends on imported products. In particular, the inhibitory effect of Malassezi on domestic products is poor. Drugs Dissolution and stability issues are prominent.
Using the compound combination of mapofloxacin, ketoconazole, triamcinolide and permethrin, the solubility and stability of the drug are improved through acid-base neutralization method and latent solution technology, and solubilizer, viscosity enhancer and gel agent are added. , form efficient and stable real solution-type ear drops, and the appropriate pH value and hydration effect improve product stability.
It provides a highly efficient and highly stable compound ear drop liquid, which significantly improves the antibacterial activity of otitis extermination pathogens, enhances the solubility and stability of drugs, reduces toxicity and medication frequency, and significantly improves the pet otitis extermination. Treatment effects and safety.
Smart Images

Figure CN118649134B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of veterinary drug preparation preparation, and specifically relates to a veterinary marbofloxacin compound gel ear drop solution and a preparation method and application thereof. Background Art
[0002] Pets in my country are mainly dogs and cats. According to the White Paper on Pet Health Consumption, the number of pets kept in my country has increased year by year in recent years. It is estimated that by 2024, my country will have 248 million pet cats and dogs, far exceeding the 172 million in the United States (Han Na et al., 2021; Hou Kaixuan et al., 2021), and the breeding scale is estimated to reach 600 billion yuan. The continuous growth of pet breeding has also caused a series of problems.
[0003] According to the "China Veterinary Industry White Paper Series - 2022 China Pet Medical Consumption Report", among the various systemic diseases of dogs and cats, the top three cases are parasitic infections, gastrointestinal digestive system problems, and skin diseases (including ear diseases). Otitis refers to inflammation of the ear canal epithelium. Generally, otitis externa occurs first and has the highest incidence. According to statistics, the incidence of otitis externa in dogs is 5-20%, and that in cats is about 2% (Zhang Di et al., 2006). It is usually difficult to cure otitis in pets and the recurrence rate is very high. This is mainly because the ear is semi-closed and the pathogens are difficult to remove (Li Tianwei, 2007). Otitis externa is manifested as acute or chronic inflammation of the epithelium of the external auditory canal. Clinical manifestations of sick dogs and cats are frequent scratching of the ears. In severe cases, it causes hyperplasia of the ear canal cerumen glands, resulting in local swelling and pus discharge (Tian Yudong, 2019). If it is not diagnosed and treated promptly and thoroughly, it will recur, further leading to otitis media, otitis interna, and even tumors, leading to hearing impairment (Wang Zhiqun, 2021). More importantly, the pathogens of mixed ear infections are mostly zoonotic pathogens. Since pets are in close contact with their owners, pet ear infections will also threaten the health of pet owners, and thus affect the friendship and harmony between pets and pet owners. Therefore, treatment of mixed ear infections in pets is crucial.
[0004] Studies have shown that the most important factor for the high incidence of otitis externa is persistence, among which mixed infections of Malassezia pachyderma and Staphylococcus are the most common (Li Chao et al., 2016; Yi Wenjing et al., 2018). In my country, among cases of infection with mites, only 5.6% are single infections (Li Xin, 2019), and this situation is particularly common in young cats (Du Jiayue, 2022). Surveys show that among dogs and cats infected with ear mites, 61.8% of cats and 100% of dogs have co-infections with ear mites and fungi or bacteria; 6.2% of cats and 1.7% of dogs have co-infections of the three (Perego Ret al., 2014).
[0005] Table 1. Research status of compound preparations for treating pet otitis externa that have been marketed in China
[0006]
[0007] Note: Product information comes from data published by the National Veterinary Drug Basic Information Database, and market prices are obtained through surveys on JD.com, Taobao Mall, etc.
[0008] Given that otitis externa in dogs and cats is often caused by mixed infections of bacteria, fungi, and parasites, the use of compound preparations is a better choice for controlling secondary infections of otitis externa than single-ingredient treatments. For example, Zhou Jinqiang et al. (2007) pointed out that compound preparations are superior to single-ingredient preparations in controlling erythema, earwax, and itching. According to the data from the National Veterinary Drug Basic Information Database, the common ear drop products currently on the market include: imported compound products including Erfuling (containing nystatin, neomycin sulfate, triamcinolone acetonide, and permethrin), Aurizon Mafoweisu ear drops (containing marbofloxacin, clotrimazole, and dexamethasone acetate), Erkeshu compound miconazole ear drops (containing miconazole nitrate, gentamicin sulfate, and hydrocortisone acetonide) and Ertejing (containing clotrimazole, gentamicin sulfate, and betamethasone valerate), etc. Domestic compound veterinary drug products include Yierjing compound nystatin ointment (containing nystatin, neomycin sulfate, triamcinolone acetonide, and permethrin), Chongerning compound fluconazole ointment (containing fluconazole, neomycin, triamcinolone acetonide) and Pitfen compound ketoconazole ointment (containing ketoconazole and metronidazole) (Table 1).
[0009] The only compound domestically produced product that combines the four functions of anti-parasite, anti-fungal, anti-bacterial and anti-inflammatory is Yierjing Compound Nystatin Ointment, which is obviously insufficient for the treatment of mixed infection type otitis externa, which is common in pets. And from Table 1, it can be seen that the dosage form of domestic products is relatively single (ointment), and the price of imported compound products is higher than that of domestic products (Table 1), indicating that the current market share and added value of domestic ear drops are relatively low. Furthermore, from the perspective of the main drug components of compound nystatin ointment, nystatin is mostly used for Candida infections of the skin, bladder, mouth, vagina, etc. It has a poor in vitro inhibitory effect on Malassezia, is highly toxic and has poor solubility (Jiang Zhengli, 2006); neomycin belongs to the aminoglycoside class of drugs, Pseudomonas aeruginosa is naturally resistant to it, and it is ototoxic; from the perspective of dosage form, the ear ointment has poor fluidity and is a non-solid semi-solid dosage form, which has the disadvantages of insufficient uniform coverage of the deep ear canals and the surface of the ear canals of dogs and cats, and the efficacy of the drug cannot be fully exerted. At the same time, the dosage is also difficult to control, and the ointment-like drugs can easily stain the hair of dogs and cats, which is also very difficult for pet owners to clean (Fu Han et al., 2021; Li Shijie et al., 2021). Although imported products such as Aurizon and Erkeshu are in a more fluid liquid state, the suspension is not only thermodynamically unstable, but also contains drugs that are mostly in a non-dissolved state. They must first be dissolved into free molecules before they can take effect, which will undoubtedly affect the efficacy of the drug (Jiang Demei et al., 2016; Song Jiayin et al., 2018). Obviously, imported products such as Aurizon and Erkeshu have deficiencies such as poor stability and efficacy. Therefore, in order to meet people's growing demand for high-quality and low-cost products, to provide a compound ear drop product with independent intellectual property rights for pet clinics, to increase the market share of my country's dosage form products in the pet market, and to reduce the dependence of my country's pet market on imported products, it is crucial to study a new compound preparation product with anti-parasitic, anti-fungal, anti-bacterial and anti-inflammatory effects for the diagnosis and treatment of clinical otitis externa infection. In view of the complexity of the pathogens of otitis externa, this study intends to develop a compound gel ear drop of marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin, and a combination of multiple drugs in order to expand the anti-infection spectrum, improve the efficacy of each drug, reduce the dosage of each drug, reduce the toxicity of each drug and the frequency of medication, and provide a safe, efficient and stable new dosage form product for my country's veterinary clinics.
[0010] Although there are related patents that combine fluoroquinolones, azoles, pyrethroids and glucocorticoids to form a composition (application publication number: CN 109464390 A). Figure 1As shown, the "stable solution-type preparation" described in the patent (application publication number: CN 109464390 A) cannot be prepared according to the technical solution provided by the patent. In addition, a large number of studies have shown that solution preparations of fluoroquinolone drugs (such as enrofloxacin and marbofloxacin) are prone to crystallization during long-term storage (Xie Yong, 2015; Wang Qingfu et al., 2017). According to the report in the "Notice of the General Office of the Ministry of Agriculture and Rural Affairs on the Third Phase of Veterinary Drug Quality Supervision and Sampling in 2021", some commercially available enrofloxacin injection products have the problem of crystallization. It can be seen that how to prepare highly stable solution-type products of fluoroquinolone drugs is a major problem currently faced by the industry. Crystallization of drugs will lead to insufficient drug content and affect drug efficacy. Increasing the solubility of drugs in solution is an effective means to reduce drug crystallization and improve stability. Among them, the addition of solubilizers and co-solvents and salt formation are important means to increase the solubility of poorly soluble drugs. For example, the use of sodium hydroxide to react with marbofloxacin to form marbofloxacin sodium can improve the solubility of marbofloxacin and the stability of the solution dosage form. However, studies have shown that permethrin is unstable under alkaline conditions, and high pH will affect its activity. In addition, ketoconazole and triamcinolone acetonide have extremely poor water solubility, and it is undoubtedly difficult to take into account the solubility and post-dissolution stability of the four drugs at the same time. In summary, the physicochemical properties of the four types of drugs, marbofloxacin, ketoconazole, triamcinolone acetonide, and permethrin, are quite different. To prepare a compound gel ear drop of marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin with good stability, significant efficacy, and appropriate pH, a more reasonable strategy needs to be explored. Summary of the invention
[0011] The object of the present invention is to provide a highly efficient and stable compound gel ear drop of marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin. The present invention uses one or a combination of sodium glutamate, meglumine, triethanolamine, and sodium hydroxide as a cosolvent, one or a combination of n-butyric acid, lactic acid, malic acid, tartaric acid, and citric acid as an acidity regulator, one or a combination of 1,2-propylene glycol, polyethylene glycol-400, n-butanol, ethanol, and Tween 80 as a latent solvent, dimethyl sulfoxide as a solubilizer, disodium edetate as a complexing agent, polyvinyl pyrrolidone (K30) as a viscosity enhancer, carbomer (Type B 934) as a gelling agent, and preparation water as a stabilizer.
[0012] The present application firstly uses the acid-base neutralization method to prepare the sodium salt of marbofloxacin, thereby improving the solubility of marbofloxacin, and then treats it with an acidity regulator to obtain a neutral pH environment, thereby providing a suitable pH environment to ensure the stability of permethrin; then the latent dissolution technology is combined to further enhance the intermolecular interactions (such as hydrogen bonds, hydrophobic forces, etc.) between the latent solvent molecules and the drug molecules, thereby enhancing the solvent effect of the latent solvent molecules on the drug; the addition of thickeners and gelling agents further restrains the microscopic movement of the sodium salt of marbofloxacin, ketoconazole molecules, triamcinolone acetonide molecules, and permethrin molecules, thereby reducing the contact frequency between the drug molecules in the solution, thereby inhibiting the recrystallization process of the drug molecules; finally, water is cleverly used as a stabilizer to further enhance the intermolecular forces (such as hydrogen bonds) between the water molecules and the drug molecules to form hydration, thereby making the solution more stable. The above technical scheme not only solves the problem of easy crystallization of the marbofloxacin solution dosage form during long-term storage, but also provides a true solution product that is more thermodynamically stable than the commercially available suspension product. Through comprehensive and systematic formulation and process research, the present invention ingeniously formulates and compatibly combines four types of drugs with greatly different physical and chemical properties, namely, marbofloxacin, ketoconazole, triamcinolone acetonide, and permethrin, to prepare a compound ear drop solution that is superior to existing products in terms of effectiveness, safety, stability, irritation, and convenience, filling the gap that there are currently no similar true solution products at home and abroad (Table 1). The disclosed compound ear drop solution can be used to treat otitis externa in dogs and cats caused by bacteria (such as Staphylococcus pseudintermedius, Pseudomonas aeruginosa, and Escherichia coli), fungi (such as Malassezia pachydermatis), and parasites (such as ear mites). Specifically, the present invention provides the following technical solutions:
[0013] The first aspect of the present invention provides a compound gel ear drop of marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin for pets, characterized in that the components of the ear drop before mixing by mass / volume constitute the following preparation composition:
[0014] (1) Marbofloxacin 0.1~1.0%;
[0015] (2) Ketoconazole 0.1~1.0%;
[0016] (3) Triamcinolone acetonide 0.01-0.05%;
[0017] (4) Permethrin 0.1~1.0%;
[0018] (5) Solubilizer 45.0~60.0%;
[0019] (6) Latent solvent 35.0~45.0%;
[0020] (7) Solvent 0.01~0.1%;
[0021] (8) Acidity regulator 0.1~1.0%;
[0022] (9) Complexing agent 0.01~0.1%;
[0023] (10) Thickener 1.5~2.5%;
[0024] (11) Gel 0.5~1.5%;
[0025] (12) Cross-linking agent 0.05~0.5%;
[0026] (13) Flavoring agent 0.1~1.0%;
[0027] (14) Stabilizer 3.5~4.5%.
[0028] In a preferred embodiment, the components of the ear drops constitute the following formulation composition before mixing by mass / volume:
[0029] (1) Marbofloxacin 0.1~0.4%;
[0030] (2) Ketoconazole 0.5~0.8%;
[0031] (3) Triamcinolone acetonide 0.01~0.03%;
[0032] (4) Permethrin 0.5~0.8%;
[0033] (5) Solubilizer 50.0~55.0%;
[0034] (6) Latent solvent 40.0~45.7%;
[0035] (7) Solvent 0.03~0.06%;
[0036] (8) Acidity regulator: 0.40~0.68%;
[0037] (9) Complexing agent 0.02~0.04%;
[0038] (10) Thickener 1.9~2.1%;
[0039] (11) Gel 0.9~1.0%;
[0040] (12) Cross-linking agent: 0.09~1.0%;
[0041] (13) Flavoring agent 0.2~0.5%;
[0042] (14) Stabilizer 3.9~4.0%.
[0043] In a preferred embodiment, the co-solvent is selected from one or a combination of sodium glutamate, meglumine, triethanolamine, and sodium hydroxide; preferably, the co-solvent is selected from sodium hydroxide.
[0044] In another specific embodiment, the acidity regulator is one of butyric acid, lactic acid, malic acid, tartaric acid, citric acid or a combination thereof; preferably, the acidity regulator is malic acid and / or lactic acid; most preferably, lactic acid.
[0045] In another specific embodiment, the latent solvent (cosolvent) is one of 1,2-propylene glycol, polyethylene glycol-400, n-butanol, Tween 80 or a combination thereof; preferably, the latent solvent is 1,2-propylene glycol and / or polyethylene glycol-400.
[0046] In another specific embodiment, the chelating agent is one of edetate disodium and edetate calcium or a combination thereof; preferably edetate disodium.
[0047] In another specific embodiment, the stabilizer is one of formulation water, ethanol or a combination thereof; preferably formulation water.
[0048] The second aspect of the present invention is to provide a method for preparing the compound gel ear drops of marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin for pets described in the first aspect. Specifically, the method comprises the following steps:
[0049] 1) Weigh the cosolvent and complexing agent according to the formula amount, dissolve them in water, add the formula amount of marbofloxacin, stir at room temperature until completely dissolved, and set aside;
[0050] 3) Weigh the formulated amount of dimethyl sulfoxide and 1 / 4 of the formulated amount of 1,2-propylene glycol, add the formulated amount of ketoconazole, triamcinolone acetonide and permethrin, stir at room temperature until completely dissolved, and filter through a filter membrane under negative pressure vacuum to obtain solution 3); at the same time, weigh polyvinyl pyrrolidone (K30) according to the formulated amount, add it to 1 / 4 of the formulated amount of 1,2-propylene glycol, stir at room temperature until completely dissolved, and obtain solution 4); weigh carbomer (type B 934) according to the formulated amount, add it to another 1 / 2 of the formulated amount of 1,2-propylene glycol, stir at room temperature overnight until completely dissolved, and obtain solution 5)
[0051] 4) adding solution 4) to solution 3) to obtain solution 6), then adding solution 6) to 5) and stirring to mix evenly, finally adding triethanolamine in the formula amount and stirring to obtain a clear and transparent solution to obtain marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin compound gel ear drops.
[0052] In a preferred embodiment, the filtration in step 3) is performed by using a 0.22 μm membrane to remove impurities;
[0053] In another specific embodiment, the negative pressure vacuum in step 3) is -0.3 to -0.1 atmospheres;
[0054] The third aspect of the present invention is a method for improving the stability of a compound gel ear drop containing marbofloxacin, the method comprising: adding a cosolvent, a latent solvent, an acidity regulator, a complexing agent, a viscosity enhancer and a stabilizer to the compound ear drop;
[0055] In a preferred embodiment, the co-solvent is selected from one or a combination of sodium glutamate, meglumine, triethanolamine, and sodium hydroxide; preferably, the co-solvent is selected from sodium hydroxide.
[0056] In another specific embodiment, the acidity regulator is one of butyric acid, lactic acid, malic acid, tartaric acid, citric acid or a combination thereof; preferably, the acidity regulator is malic acid and / or lactic acid; most preferably, lactic acid.
[0057] In another specific embodiment, the latent solvent is one or a combination of 1,2-propylene glycol, polyethylene glycol-400, n-butanol, ethanol; preferably, the latent solvent is 1,2-propylene glycol and / or polyethylene glycol-400.
[0058] In another specific embodiment, the chelating agent is one of edetate disodium and edetate calcium or a combination thereof; preferably edetate disodium.
[0059] In another specific embodiment, the viscosity increasing agent is polyvinyl pyrrolidone K30.
[0060] In another specific embodiment, the stabilizer is one of formulation water, ethanol or a combination thereof; preferably formulation water.
[0061] In another preferred embodiment, the compound gel ear drops containing marbofloxacin are marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin compound gel ear drops.
[0062] The fourth aspect of the present invention is the use of the marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin compound gel ear drops for pets in treating single or mixed bacterial, fungal and parasitic infections in the ears of pets.
[0063] In a specific embodiment, the bacteria include but are not limited to Staphylococcus pseudintermedius, Pseudomonas aeruginosa, Escherichia coli, Streptococcus, Proteus, etc.; the fungi include but are not limited to Malassezia pachydermatis, Candida, Microsporum, etc.; the parasites include but are not limited to ear mites, scabies, etc.
[0064] The beneficial effects of the present invention are as follows:
[0065] The advantages of the highly effective and highly stable Marbofloxacin compound gel ear drops for pets provided by the present invention are as follows: (1) Properties: The compound of the present application is in the form of a true solution, and does not crystallize after long-term (180 days) storage at low temperature (4°C) and accelerated temperature (30°C). Its stability is significantly higher than that of Aurizon and Erkeshu, which are suspensions; (2) Irritation: The pH value of the compound of the present application is 6.43, which is closer to a neutral environment than Aurizon (pH=3.90) and Erkeshu (pH=3.76) (Table 21), and the compound provided by the present application has stronger compliance; (3) Antibacterial activity: Compared with other marketed products (such as Aurizon), the MIC of the compound ear drops against common pathogens of otitis externa such as Staphylococcus pseudintermedius and Malassezia pachydermatis is significantly smaller, and the inhibition zone is larger (Tables 18-20), and the compound provided by the present application has stronger antibacterial activity; (4) Treatment effect of mixed infection model: For the mixed infection model of drug-resistant bacteria and fungi, the compound of the present application is in the fourth The wounds in the Aurizon group had scabs and improved significantly by 1.5 days, while the wounds in the Aurizon group still showed signs of suppuration after the treatment. Fig.13 ), and after treatment with this compound, the efficiency of reducing the amount of bacteria in the ear canal was significantly better than that of Aurizon ( Fig.13 ), the compound provided in this application has a significantly stronger therapeutic effect on drug-resistant bacterial infections; (5) Efficacy: In the clinical treatment trial of dogs with otitis externa, the significant improvement rate of the compound on dogs with otitis externa reached 89.5% (17 / 19), the overall effective rate reached 94.7% (18 / 19), and no cases of recurrence occurred after the end of the treatment course. The compound has excellent clinical efficacy; (6) Safety: The compound was used in rabbits at 5 times the recommended dose, and still did not significantly affect the blood physiological state and liver and kidney functions of the rabbits. The provided compound has high safety ( Fig.12 ).
[0066] The ear drop compound provided in this application fills the gap that there are currently no similar true solution products at home and abroad. It is significantly superior to existing products (such as Aurizon) in terms of stability, irritation, antibacterial activity, effectiveness, and safety, and has a large market prospect. The further development of this compound is conducive to improving the market share and pricing power of my country's veterinary products, and is an active practice of my country's "independent innovation of new drugs" strategy. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] Figure 1 . Dissolution of drugs with different feed ratios in compound systems;
[0068] Figure 2The compound solution prepared based on the technical solution disclosed in the invention patent application (CN 109464390 A) is as follows: A solution a formed by dissolving ketoconazole and ciprofloxacin hydrochloride in propylene glycol and adding hydroxypropyl β-cyclodextrin; B solution b formed by dissolving permethrin and fluocinolone acetate in dimethyl sulfoxide and diethylene glycol monoethyl ether; C solution a and solution b are mixed; D solution a' is obtained by dissolving ketoconazole in diethylene glycol monoethyl ether; E solution b' is obtained by dissolving ciprofloxacin hydrochloride, permethrin and fluocinolone acetate in dimethyl sulfoxide; F solution a' is mixed with solution b';
[0069] Figure 3 The compound solutions prepared based on the technical solution disclosed in the invention patent application (CN 112245438 A) are as follows: A 0.2 g salicylic acid is added to a system of 20 mL ethanol and 80 mL water, B 0.2 g salicylic acid is added to a system of 20 mL ethanol and 80 mL water, C 0.2 g marbofloxacin and 0.1 g salicylic acid are added to a system of 20 mL ethanol and 80 mL water, D 0.2 g marbofloxacin and 0.14 g salicylic acid are added to a system of 20 mL ethanol and 80 mL water, E 0.2 g marbofloxacin and 0.2 g salicylic acid are added to a system of 20 mL ethanol and 80 mL water, F 0.2 g marbofloxacin and 0.3 g salicylic acid are added to a system of 20 mL ethanol and 80 mL water;
[0070] Figure 4 Comparison of the inhibition zones of commercially available products and the compound gel ear drops of the present invention against pathogenic bacteria of animal origin: AF are P.aeruginosa 22017, P.aeruginosa 22026, P.aeruginosa 22515, P.aeruginosa22532, P.aeruginosa 22142, P.aeruginosa 22631, which are diagrams of the inhibition zones of each commercially available product and the ear drops of the present application; GH are E.coli 211192, E.coli 211192, which are diagrams of the inhibition zones of each commercially available product and the ear drops of the present application; IN are S.pseudintermedius 22503, S.pseudintermedius 22022, S.pseudintermedius 22263, S.pseudintermedius 22191, S.pseudintermedius 22130, S.pseudintermedius 22737 Graphical representation of the inhibition zones of various commercially available products and the ear drops of the present application;
[0071] Figure 5Comparison of the inhibition zones of commercially available products and the compound gel ear drops of the present invention against pathogenic fungi of animal origin: AC are diagrams showing the inhibition zones of M.pachydermatis CAUF107, M.pachydermatis CAUF108, and M.pachydermatis CAUF109 against each commercially available product and the ear drops of the present application;
[0072] Figure 6 The instructions for commercially available Aurizon Mafo Micro-Sugar;
[0073] Figure 7 Instructions for commercially available compound miconazole ear drops (Er Ke Shu);
[0074] Figure 8 Comparison of centrifugal stability between commercially available products and the compound gel ear drops of the present invention: A. Initial phase of the ear drops of the present invention and the commercially available products before centrifugation, B. Stratification of the ear drops of the present invention and the commercially available products after centrifugation, wherein: a: Erkeshu compound miconazole ear drops, b: Aurizon Mafo Micro-Su ear drops, c: Yierjing compound nystatin ointment, d: compound ketoconazole ointment, e: compound gel ear drops of the present invention;
[0075] Fig. 9 Comparison of viscosity between commercially available products and the compound gel ear drops of the present invention: A viscosity curve of the compound gel ear drops after 0 days of storage in the accelerated stability test, B viscosity curve of the compound gel ear drops after 180 days of storage in the accelerated stability test, C viscosity curve of the commercially available compound miconazole ear drops (Er Ke Shu);
[0076] Fig.10 Skin irritation of the compound gel ear drops of the present invention: A single stimulation, B multiple stimulation;
[0077] Fig.11 Effects of the compound gel ear drops of the present invention on blood routine and blood biochemistry of rabbits;
[0078] Fig.12 The histopathological effects of the compound gel ear drops of the present invention on the ears, liver and kidneys of rabbits;
[0079] Fig.13 A diagram showing the therapeutic effects of commercially available products and the compound gel ear drops of the present invention on a rabbit ear resistant fungus and bacterial mixed infection model;
[0080] Fig.14 Statistical graph of bacterial loads after treatment of a rabbit ear resistant fungus and bacteria mixed infection model by commercially available products and the compound gel ear drops of the present invention;
[0081] Fig.15 A statistical graph of the scores of the compound gel ear drops of the present invention on dogs suffering from otitis externa;
[0082] Fig.16 Comparison of ears of dogs with otitis externa before and after treatment with the compound gel ear drops of the present invention. DETAILED DESCRIPTION
[0083] The present invention is further described below in conjunction with specific embodiments. Those skilled in the art should understand that the details and forms of the technical solutions of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements are all within the scope of protection of the present invention.
[0084] Example 1 Determination of the type of solvent in the compound gel ear drops
[0085] The solubility of marbofloxacin, ketoconazole, triamcinolone acetonide and permethrin in dimethyl sulfoxide, 1,2-propylene glycol and other solvents (1 mL each) was measured. The results are shown in Table 2. It can be seen that the solubility of ketoconazole, triamcinolone acetonide and permethrin in dimethyl sulfoxide is significantly greater than that in 1,2-propylene glycol, so dimethyl sulfoxide was used as a solubilizer in the subsequent reaction.
[0086] Table 2. Determination of solubilizer types
[0087]
[0088] Example 2 Determination of the ratio of active ingredients added to the ear drop compound
[0089] The active ingredients in the compound gel ear drops of the present invention are marbofloxacin, ketoconazole, triamcinolone acetonide and permethrin. Due to the large differences in the physical and chemical properties of the components, the feed ratio needs to be determined through trial and error. According to the solubility of each drug in dimethyl sulfoxide and 1,2-propylene glycol in Table 2, according to the W / V ratio, 0.6% permethrin, 1.2% ketoconazole, 0.02% triamcinolone acetonide, 0.33% marbofloxacin, 50% dimethyl sulfoxide, and 40% 1,2-propylene glycol were first selected for dissolution test. Figure 1 As shown in the figure, 1.2% ketoconazole cannot be completely dissolved; the dissolution of marbofloxacin is poor. From Table 2, we can also conclude that the solubility of marbofloxacin in dimethyl sulfoxide and 1,2-propylene glycol is relatively low. Therefore, it is necessary to explore a suitable way to dissolve the active ingredient of marbofloxacin. The feed ratio is proposed to be: marbofloxacin (~0.33%); ketoconazole (~0.6%); triamcinolone acetonide (~0.02%); permethrin (~0.6%).
[0090] Example 3 Determination of the type of cosolvent in the compound gel ear drops
[0091] In view of the chemical structure of marbofloxacin, which has a carboxyl group, alkali was considered to dissolve marbofloxacin. First, saturated sodium glutamate, meglumine, triethanolamine, and sodium hydroxide solutions were prepared, and 2.5g of marbofloxacin was dissolved in the saturated solutions until it was completely dissolved, and the volume of the saturated solutions used was recorded. The results showed that the solubilizing effect of the co-solvent on marbofloxacin was sodium hydroxide, triethanolamine, sodium glutamate, and meglumine from strong to weak, so sodium hydroxide was selected as the co-solvent of the compound ear drops.
[0092] Example 4 Determination of the type of acidity regulator in the compound gel ear drops
[0093] 5 mL of 2.5% sodium hydroxide solution was used to completely dissolve 0.825 g of marbofloxacin to obtain five portions of alkaline marbofloxacin solution, to which 10 mL of water was added, and then 20.0% n-butyric acid, lactic acid, malic acid, tartaric acid, and citric acid solutions were added dropwise to adjust the pH to acidic, and the amount of acid solution used in this process was recorded. The obtained clear solution was left to stand at room temperature to observe the crystallization of the solution. The results are shown in Table 3. Precipitation was observed within 48 h in the tartaric acid and phosphoric acid groups. The volume used for acidity adjustment of lactic acid and citric acid was less and no precipitation was observed after standing at room temperature for 48 h. However, the cost of citric acid raw materials was relatively high, so lactic acid was selected as the acidity regulator of the compound gel ear drops.
[0094] Table 3. Determination of acidity regulators for compound gel ear drops
[0095]
[0096] Example 5 Determination of the type of co-solvent in the compound gel ear drops
[0097] The types and amounts of excipients in the formula are shown in Table 4:
[0098] Table 4. Types and dosages of excipients in a compound gel ear drop solution
[0099]
[0100] According to the types and amounts of auxiliary materials listed in Table 4, weigh the required amount and prepare according to the following preparation method:
[0101] 1) Weigh sodium hydroxide and complexing agent (disodium edetate) according to the amount in Table 4, dissolve them in water, add the formulated amount of marbofloxacin, stir at room temperature until completely dissolved, and set aside;
[0102] 2) Weigh the acidity regulator (lactic acid) according to the amount in Table 4, add it dropwise into the solution in 1), stir until completely dissolved, and set aside;
[0103] 3) Weigh dimethyl sulfoxide according to the amount in Table 4, add one of ethanol / n-butanol / propylene glycol / polyethylene glycol-400 as a latent solvent according to the amount shown in Table 4, add ketoconazole, triamcinolone acetonide and permethrin in the formula amount, stir at room temperature until completely dissolved, and set aside;
[0104] 4) Add the solution in 2) to solution 3) and stir continuously until a clear mixed solution is obtained. Filter the mixture through a membrane under negative pressure to remove impurities and set aside.
[0105] 5) Weigh the stabilizer (water for preparation), viscosity enhancer (polyvinyl pyrrolidone), gelling agent (carbomer) and cross-linking agent (triethanolamine) according to the amounts in Table 4, add to the filtrate in 4), and stir at room temperature overnight until completely dissolved to obtain a marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin compound gel ear drops.
[0106] The five compound gel ear drops containing different co-solvents were placed in a 4°C incubator for 30 days, during which the crystallization was observed every day and recorded in Table 5. As shown in Table 5, compared with the group without co-solvent, the Tween-80, n-butanol, ethanol, 1,2-propylene glycol and polyethylene glycol-400 groups all improved the crystallization of the compound gel ear drops, among which the 1,2-propylene glycol group still did not observe crystallization at 30 days, so 1,2-propylene glycol was used as a co-solvent in the subsequent preparation process.
[0107] Table 5. Crystallization of compound gel ear drops containing different co-solvents
[0108]
[0109] Note: The positive control is the group without co-solvent, and the rest are the same.
[0110] Example 6 Determination of stabilizer in compound gel ear drops
[0111] The types and amounts of excipients in the formula are shown in Table 6:
[0112] Table 6. Types and dosages of excipients in a compound gel ear drop solution
[0113]
[0114] According to the types and amounts of auxiliary materials listed in Table 6, weigh the required amount and prepare according to the following preparation method:
[0115] 1) Weigh the cosolvent (sodium hydroxide) and the complexing agent (disodium edetate) according to Table 6, dissolve them in different amounts of the preparation with water, add the formulated amount of marbofloxacin, stir at room temperature until completely dissolved, and set aside;
[0116] 2) Weigh the acidity regulator according to Table 6, add it dropwise into the solution in 1), stir until it is completely dissolved, and set aside;
[0117] 3) Weigh dimethyl sulfoxide according to the amount in Table 6, add 1,2-propylene glycol according to the amount shown in Table 6, add ketoconazole, triamcinolone acetonide and permethrin in the formula, stir at room temperature until completely dissolved, and set aside;
[0118] 4) Add the solution in 2) to solution 3) and stir continuously until a clear mixed solution is obtained. Filter the mixture through a membrane under negative pressure to remove impurities and set aside.
[0119] 5) Weigh the viscosity enhancer, gelling agent and cross-linking agent according to the amounts in Table 6, add them to the filtrate prepared in 4), and stir at room temperature overnight until they are completely dissolved to obtain a marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin compound gel ear drops.
[0120] The above five kinds of compound gel ear drops containing different amounts of stabilizers were placed in a 4°C incubator for 30 days, during which the crystallization was observed every day and recorded in Table 7. As shown in Table 7, compared with the group without stabilizer, the 4%, 6%, 8%, and 10% preparation water (stabilizer) groups all improved the crystallization of the compound gel ear drops, among which the 4% group still did not observe crystallization at 30 days (Table 7), so the 4% stabilizer dosage was used as a screening reference in the subsequent preparation process.
[0121] Table 7. Crystallization of compound gel ear drops containing different amounts of stabilizers
[0122]
[0123] Note: The positive control is the group without stabilizer, and the rest are the same.
[0124] Example 7 Determination of viscosity enhancer and gelling agent in compound gel ear drops
[0125] The types and amounts of excipients in a compound ear drops formulation are shown in Table 8:
[0126] Table 8. Types and dosages of excipients in a compound gel ear drop solution
[0127]
[0128] According to the types and amounts of auxiliary materials listed in Table 8, weigh the required amount and prepare according to the following preparation method:
[0129] 1) Weigh the cosolvent (sodium hydroxide) and the complexing agent (disodium edetate) according to Table 8, dissolve them with the stabilizer, then add the formulated amount of marbofloxacin, stir at room temperature until completely dissolved, and set aside;
[0130] 2) Weigh the acidity regulator according to the amount in Table 8, add it dropwise into the solution in 1), stir until it is completely dissolved, and set aside;
[0131] 3) Weigh dimethyl sulfoxide according to the amount in Table 8, add 1,2-propylene glycol as a latent solvent according to the amount shown in Table 8, add ketoconazole, triamcinolone acetonide and permethrin in the formula amount, stir at room temperature until completely dissolved, and set aside;
[0132] 4) Add the solution in 2) to solution 3) and stir continuously until a clear mixed solution is obtained. After filtering through a membrane under negative pressure to remove impurities, the mixture is divided into three portions;
[0133] 5) One portion of the above-mentioned mixed solution was added with 2% thickener, and the other portion was added with 2% thickener, 1% gelling agent, and 0.08% cross-linking agent, and they were placed in a 4°C incubator for 30 days, during which the crystallization was observed every day and recorded in Table 9. As shown in Table 9, compared with the group without thickener, the groups with thickener and gelling agent improved the crystallization of the compound gel ear drops, and no crystallization was observed in the group with thickener and gelling agent at 30 days. Therefore, in the subsequent preparation process, the group with 2% thickener, 1% gelling agent, and 0.08% cross-linking agent was proposed as the optimal group.
[0134] Table 9. Crystallization of compound gel ear drops with thickener and gelling agent added
[0135]
[0136] Note: The positive control is the group without thickener, gelling agent and cross-linking agent, and the rest is the same.
[0137] Example 8 Determination of the ratio of viscosity enhancer, gelling agent and stabilizer in compound gel ear drops
[0138] As mentioned above, the physical properties, light, thermal stability, and solubility of the active ingredients in this application - Marbofloxacin, ketoconazole, triamcinolone acetonide, and permethrin - vary greatly. As can be seen from Examples 6 and 7, stabilizers, thickeners, and gelling agents are crucial to the stability of the compound ear drops, and there is a mutual influence between the three. Therefore, in this application, the crystallization stability of 180 days in accelerated (30°C) and low temperature (4°C) environments is used as an investigation indicator, and an orthogonal experimental design is adopted to comprehensively and systematically study the optimal addition ratio of stabilizers, thickeners, and gelling agents to prepare stable compound gel ear drops. The addition amounts of stabilizers, thickeners, and gelling agents in each group of the orthogonal design are shown in Table 10.
[0139] Table 10. Settings of variables and levels in orthogonal design
[0140]
[0141] Accelerated stability test: Place the packaged compound gel ear drops at 30°C, take out a small amount of liquid at 0, 1, 2, 3, and 6 months to measure its pH, and use high performance liquid chromatography (HPLC) to detect the content of active ingredients and related substances in the solution. At the same time, observe the visible foreign matter, crystallization, appearance color, etc. to judge the stability of the compound preparation of the present invention.
[0142] Low temperature stability test: Place the packaged compound gel ear drops at 4°C and examine the crystallization of the prepared compound solution at 0, 1, 2, 3, and 6 months to evaluate the low temperature stability of the compound solution.
[0143] Test results table
[0144] Table 11. Crystallization in 4℃ accelerated stability test
[0145]
[0146] Note: - indicates no crystal precipitation; + indicates a small amount of crystal precipitation; ++ indicates moderate crystal precipitation; ++++ indicates a large amount of crystal precipitation
[0147] Table 12. Crystallization and pH changes in 30℃ accelerated stability test
[0148]
[0149] Note: - indicates no crystal precipitation; + indicates a small amount of crystal precipitation; ++ indicates moderate crystal precipitation; ++++ indicates a large amount of crystal precipitation; / indicates not determined.
[0150] Table 13. Marbofloxacin content in 30℃ accelerated stability test (g / 250mL)
[0151]
[0152] Table 14. Ketoconazole content in 30℃ accelerated stability test (g / 250mL)
[0153]
[0154] Table 15. Triamcinolone acetonide content in 30℃ accelerated stability test (g / 250mL)
[0155]
[0156] Table 16. Permethrin content in 30℃ accelerated stability test (g / 250mL)
[0157]
[0158] 2. Description of test results
[0159] As shown in Examples 6 and 7, stabilizers, thickeners and gelling agents are crucial to the stability of the compound ear drops, and there may be mutual influence among the three. Therefore, in this application, the crystallization stability of 180 days in accelerated (30°C) and low temperature (4°C) environments is used as an investigation indicator, and an orthogonal experimental design is adopted to comprehensively and systematically study the optimal addition ratio of stabilizers, thickeners and gelling agents. According to the results of Tables 11-16, among the groups with different amounts of water, polyvinyl pyrrolidone and carbomer, only the combination of Groups 2, 5, 6 and 8 did not crystallize when accelerated at 30°C and 4°C for 180 days (Table 11, Table 12), and the pH of marbofloxacin, ketoconazole, triamcinolone acetonide and permethrin in Group 8 was 180 °C. There was no significant change within d (Tables 13-16), therefore, group 8 was the optimal group. The other components and specific contents of group 8 were shown in Table 6. In addition, based on the results of the orthogonal experiment, we determined the addition ratio of 4% water, 2% polyvinyl pyrrolidone and 1% carbomer in group 8 as the optimal amount of stabilizer, thickener and gelling agent in the compound ear drops.
[0160] Example 9 Screening of the Optimal Preparation Method for Compound Gel Ear Drops
[0161] In order to ensure that the prepared compound gel ear drops have a clearer appearance and better quality, we screened the optimal method of adding thickeners and gelling agents. If the weighed thickener and gelling agent powders are directly added to the prepared system, the resulting solution will not be clear in appearance; if a certain amount of 1,2-propylene glycol is used to dissolve the thickener and gelling agent powders respectively and then added to the prepared system in sequence, a clearer solution can be obtained. The clarity of the ear drops obtained by the above different preparation methods is different. We screened the amount of propylene glycol and found that when the thickener is dissolved with 10% 1,2-propylene glycol and the gelling agent is dissolved with 20% 1,2-propylene glycol, the thickener and gelling agent powders can be completely dissolved, so it is determined to be the optimal preparation process.
[0162] Example 10 Repetition of the technical solution provided in the invention patent application (application publication number: CN 109464390 A)
[0163] The preparation of the compound solution of permethrin-ketoconazole-ciprofloxacin hydrochloride-fluocinolone acetate was carried out according to the method described in the embodiment of the invention patent application (application publication number: CN 109464390 A). The experiment confirmed that both the embodiment 1 and the embodiment 2 in the control patent had the following defects:
[0164] (1) According to Example 1 of the patent application (CN 109464390 A), the excipients are actually unable to completely dissolve the drug: the contents of Example 1 of the patent, “After ketoconazole and ciprofloxacin hydrochloride are dissolved in propylene glycol, hydroxypropyl β-cyclodextrin is added to obtain solution a”, and “permethrin and fluocinolone acetate are dissolved in dimethyl sulfoxide and diethylene glycol monoethyl ether to obtain solution b” are actually milky white suspensions rather than the solutions described in the patent application (CN 109464390 A) ( Figure 2 A in Figure 2 B in the patent application); "Solution a and solution b are mixed, and carbomer is added to obtain a completely clear finished product" is actually a light pink precipitate state rather than the clear state described in the patent application (CN 109464390 A) ( Figure 2 C in.
[0165] (2) According to the description in Example 2 of the patent application (CN 109464390 A), the excipients still cannot completely dissolve the drug: the contents in Example 2 of the patent application, "ketoconazole is dissolved in diethylene glycol monoethyl ether to obtain solution a'", "ciprofloxacin hydrochloride, permethrin and acetic acid fluoride are dissolved in dimethyl sulfoxide to obtain solution b'" and "solution a' and solution b' are mixed and then butylated hydroxyanisole is added to obtain a completely clear finished product" are actually milky white suspensions rather than the clear solutions described in the patent application (CN 109464390 A). Figure 2 D in Figure 2 E in Figure 2 F in.
[0166] The technical method described in the invention patent application (CN 109464390 A) cannot produce the "clarified" permethrin-ketoconazole-ciprofloxacin hydrochloride-fluocinolone acetonide compound solution described therein, that is, the technical solution disclosed in the invention patent application (CN 109464390 A) cannot provide reference for this application.
[0167] Example 11 The example of increasing the solubility of marbofloxacin with salicylic acid proposed in the invention patent application (application publication number: CN 112245438 A) was repeated.
[0168] The invention patent application (application publication number: CN 112245438 A) discloses a marbofloxacin-ketoconazole-cortisol compound solution. According to Example 3 of the invention patent application (CN 112245438 A), "salicylic acid can promote the dissolution of marbofloxacin and the resulting solution is very stable." The technical solution was repeated and it was found that there were contents inconsistent with the patent description:
[0169] According to the description in Example 3 of the patent (CN 112245438 A), salicylic acid does not actually have a solubilizing effect on marbofloxacin: the content in Example 3 of the patent application document, "when only 0.2 g of marbofloxacin is added to a system of 20 mL ethanol and 80 mL water, the entire system does not dissolve", is actually a dissolved state rather than the insoluble state described in the patent (CN 112245438 A). Figure 3 A in the patent); "When only 0.2 g of salicylic acid is added to a system of 20 mL of ethanol and 80 mL of water, the entire system is completely dissolved" is actually an insoluble state rather than a clear solution state as described in the patent ( Figure 3 B in the patent); "When 0.2 g of marbofloxacin and 0.1 g of salicylic acid are added to a system of 20 mL of ethanol and 80 mL of water, the entire system is completely dissolved" is actually an undissolved state rather than a clear solution state as described in the patent ( Figure 3 C) "When 0.2 g of marbofloxacin and 0.14 g of salicylic acid are added to a system of 20 mL of ethanol and 80 mL of water, the entire system is completely dissolved" is actually an undissolved state rather than the clear solution state described in the patent ( Figure 3 D) "When 0.2 g of marbofloxacin and 0.2 g of salicylic acid are added to a system of 20 mL of ethanol and 80 mL of water, the entire system is completely dissolved" is actually an undissolved state rather than the clear solution state described in the patent ( Figure 3 E) "When 0.2 g of marbofloxacin and 0.3 g of salicylic acid are added to a system of 20 mL of ethanol and 80 mL of water, the entire system is completely dissolved" is actually an insoluble state rather than the clear state described in the patent ( Figure 3 F in.
[0170] Obviously, the technical method described in the invention patent application (CN 112245438 A) still cannot solve the problem of how to prepare a true solution dosage form when marbofloxacin is combined with ketoconazole, etc., that is, the technical solution disclosed in the invention patent (CN 112245438 A) cannot provide a reference for this application. Based on this, in order to provide a marbofloxacin-ketoconazole-triamcinolone acetonide-permethrin compound solution preparation product and enhance the international competitiveness of my country's veterinary drug companies, the present invention has proposed a more reasonable technical solution after detailed and careful research on the formulation and compatibility.
[0171] Example 12 Comparison of MIC values of Aurizon ear drops, Erkeshu compound miconazole ear drops, marbofloxacin standard and the compound gel ear drops of the present application against pathogenic bacteria isolated from the ears of pets
[0172] Pseudomonas aeruginosa, Escherichia coli and Staphylococcus pseudointermedia isolated from the pet's ear canal were revived and subcultured. Microbroth dilution susceptibility test was performed according to the method specified by CLSI to compare the antibacterial efficacy of various commercially available products, the patented compound gel ear drops and marbofloxacin standard. The specific method is as follows:
[0173] 1) Dilute the original bacterial solution in the logarithmic phase with fresh broth medium to a concentration of about 106 CFU / mL;
[0174] 2) dilute the Aurizon ear drops with fresh broth medium to a first-well concentration of 4 μg / mL (Staphylococcus pseudointermedius), 8 μg / mL (Pseudomonas aeruginosa), and 1 μg / mL (Escherichia coli) of marbofloxacin, dilute the Earcos ear drops with fresh broth medium to a first-well concentration of 4 μg / mL of gentamicin, dilute the ear drops covered by this patent to a first-well concentration of 4 μg / mL of marbofloxacin, and dilute the marbofloxacin standard to a first-well concentration of 4 μg / mL;
[0175] 3) Use fresh broth medium to spread on a 96-well cell culture plate, 100 μL per well;
[0176] 4) Add 100 μL of each drug solution to the first well of rows A and H respectively;
[0177] 5) The drug solution in column 1 is diluted in multiples to column 10 and then discarded;
[0178] 6) Add the bacterial solution to each well in columns 1-11, 100 μL / well;
[0179] 7) Place each 96-well cell culture plate in a 37°C incubator for 16-24 hours and read the MIC value.
[0180] The MIC results of different ear drop products are shown in Table 17. The results show that the MIC of the ear drop compound of the present application against bacterial pathogens such as Pseudomonas aeruginosa, Escherichia coli and Staphylococcus pseudintermedius is better or equivalent than that of commercially available products such as Aurizon, indicating that the compound ear drops of the present invention have better formulation advantages and antibacterial activity.
[0181] Table 17. MIC results of different ear drop products (μg / mL)
[0182]
[0183] Note: The MIC value of this compound is based on the concentration of marbofloxacin.
[0184] Example 13 Comparison of the inhibition zones of Aurizon ear drops, Erkeshu compound miconazole ear drops, marbofloxacin standard, Yierjing compound nystatin ointment, compound ketoconazole ointment and the compound gel ear drops of the present invention on pathogenic bacteria isolated from the ears of pets
[0185] Pseudomonas aeruginosa, Escherichia coli and Staphylococcus pseudointermedia isolated from the ear canal of pets were revived and passaged. The paper strip method drug sensitivity test was carried out according to the method specified by CLSI to examine the efficacy of various commercially available products, this patented product and marbofloxacin standard. The specific method is as follows:
[0186] 1) Dilute the original bacterial solution in the logarithmic phase with fresh broth medium to a concentration of about 106 CFU / mL;
[0187] 2) Take 20 mL of autoclaved broth agar medium, add 200 μL of bacterial solution, mix well, inject into a 9 cm plate, and dry until there is no moisture;
[0188] 3) Mark the approximate location of each drug-loaded paper on the back of the dish;
[0189] 4) Pipette 5 μL of drug solution onto a clean filter paper. After the drug solution is completely absorbed, stick the drug-loaded paper to the corresponding position;
[0190] 5) Place each plate in an incubator at 37°C and incubate for 16-24 hours, then measure and take photos to record the inhibition zone.
[0191] The inhibition zone results of different ear drops products are shown in Table 18 and Figure 4As shown (AF are P.aeruginosa22017, P.aeruginosa 22026, P.aeruginosa 22515, P.aeruginosa 22532, P.aeruginosa 22142, P.aeruginosa 22631 respectively, which are diagrams of the inhibition zones of various commercially available products and the ear drops of the present application; GH are E.coli 211192, E.coli 211192 respectively, which are diagrams of the inhibition zones of various commercially available products and the ear drops of the present application; IN are S.pseudintermedius 22503, S.pseudintermedius 22022, S.pseudintermedius 22263, S.pseudintermedius 22191, S.pseudintermedius 22130, S.pseudintermedius 22737 for each commercially available product and the ear drops of the present application), the results show that the ear drops of the present invention have a larger or equivalent inhibition zone against bacterial pathogens such as Pseudomonas aeruginosa, Escherichia coli and Staphylococcus pseudintermedius than Aurizon and other commercially available products, indicating that the compound ear drops of the present invention have better formulation advantages and antibacterial activity.
[0192] Table 18. Diameter of inhibition zone of each product (mm)
[0193]
[0194] Example 14 Comparison of MIC values of ketoconazole standard, Erkeshu ear drops, Aurizon ear drops, and compound gel ear drops against pathogenic fungi
[0195] Resuscitate Malassezia pachydermatis and subculture.
[0196] The microbroth dilution method was used to perform drug sensitivity testing according to the method specified by CLSI, and the antibacterial efficacy of each commercially available product, this patented product, and ketoconazole standard was compared. The specific method is as follows:
[0197] 1) Scrape off the well-growing Malassezia pachydermatis colonies on the SDA medium containing 1% Tween 80, adjust the turbidity to 0.5 with sterile water, and dilute the bacterial solution 1000 times;
[0198] 2) Use fresh Leeming & Notman medium to dilute Aurizon ear drops to a first-well concentration of 4 μg / mL of clotrimazole, dilute Erkeshu ear drops to a first-well concentration of 4 μg / mL of miconazole, dilute the ear drops covered by this patent to a first-well concentration of 4 μg / mL of ketoconazole, and dilute ketoconazole standard to a first-well concentration of 4 μg / mL;
[0199] 3) Use fresh Leeming & Notman medium to spread 100 μL per well of a 96-well cell culture plate;
[0200] 4) Add 100 μL of each drug solution to the first well of rows A and H respectively;
[0201] 5) The drug solution in column 1 is diluted in multiples to column 10 and then discarded;
[0202] 6) Add the bacterial solution to each well in columns 1-11, 100 μL / well;
[0203] 7) Place each 96-well cell culture plate in a 35°C incubator for 72 hours and read the MIC value.
[0204] The MIC results of different ear drop products against pathogenic fungi are shown in Table 19, and the results show that the MIC of the ear drop compound of the present invention against Malassezia pachydermatis is significantly better than that of commercial products such as Aurizon. It is worth mentioning that although the Aurizon compound contains the antifungal drug clotrimazole (Table 1), the actual inhibitory effect of Aurizon on Malassezia pachydermatis is not ideal. This may be because the clotrimazole in the suspension state of Aurizon is not completely dissolved into free molecules, which limits the antibacterial effect of clotrimazole. This shows that the solution state is more conducive to the antibacterial activity of the drug. The solution-like compound ear drops provided in this application have better formulation advantages and antibacterial activity than commercially available products.
[0205] Table 19. MIC test results of different products against pathogenic fungi (μg / mL)
[0206]
[0207] Note: The MIC value of this compound is based on the concentration of ketoconazole.
[0208] Example 15 Inhibition zone test of ketoconazole standard, Erkeshu ear drops, compound ketoconazole ointment, Aurizon ear drops, Yierjing, and compound gel ear drops against pathogenic fungi
[0209] Resuscitate Malassezia pachydermatis and subculture it.
[0210] The antibacterial efficacy of commercially available products, this patented product, and ketoconazole standard products was examined by conducting a paper strip drug sensitivity test according to the method specified by CLSI. The specific method is as follows:
[0211] 1) Scrape fresh colonies grown on 1% Tween 80 SDA medium and dilute the original bacterial solution with fresh modified Martin medium to a turbidity of 0.5;
[0212] 2) Take 20 mL of autoclaved 1% Tween 80 SDA medium, add 200 μL of bacterial solution, mix well, inject into a 9 cm plate, and dry until there is no moisture;
[0213] 3) Mark the approximate location of each drug-loaded paper on the back of the dish;
[0214] 4) Pipette 5 μL of drug solution onto a clean filter paper. After the drug solution is completely absorbed, stick the drug-loaded paper to the corresponding position;
[0215] 5) After incubating each plate in an incubator at 35°C for 72 h, take photos and measure the inhibition zone, as shown in Table 20 and Figure 5 As shown (AC are diagrams of the inhibition zones of M.pachydermatis CAUF107, M.pachydermatis CAUF108, and M.pachydermatis CAUF109 against various commercially available products and the ear drops of the present application).
[0216] The results of the inhibition zones of different ear drops products against pathogenic fungi are shown in Table 20. The results show that the inhibition zone of the ear drops compound of the present invention against Malassezia thaliana is significantly better than that of commercial products such as Aurizon and compound ketoconazole ointment. It is worth mentioning that although the Aurizon compound contains the antifungal drug clotrimazole (Table 1), the actual inhibitory effect of Aurizon on Malassezia thaliana is not ideal. This may be due to the fact that the clotrimazole in Aurizon in the suspension state is not completely dissolved into free molecules, which limits the antibacterial effect of clotrimazole, indicating that the solution state is more conducive to the antibacterial activity of the drug. And compared with the ketoconazole standard and the compound ketoconazole ointment, although the antifungal active ingredients of the three are all ketoconazole, the compound inhibition zone of the present application is significantly larger, which indicates that there is a synergistic or additive effect in each formulation of the compound ear drops provided by the present invention, and it has better formulation advantages and antibacterial activity.
[0217] Table 20. Diameter of inhibition zone (mm)
[0218]
[0219] Example 16 Comparison of the stability of the compound gel ear drops of the present invention with Aurizon and Erkeshu
[0220] The instructions for commercially available products are as follows: Figure 6 (Aurizon), Figure 7As shown in the examples of the two medicines (Erkeshu), Aurizon emphasizes "Shake well before use", which obviously shows that Aurizon is a suspension and has the disadvantage of poor stability; Erkeshu emphasizes "Shake well before use and cut the hair at the medication site", which obviously shows that Erkeshu has the disadvantages of poor stability and easy to contaminate hair. The compound gel ear drops of the present invention are true solutions, which are undoubtedly more stable and more effective than the commercially available compound marbofloxacin ear drops (Aurizon) and the commercially available compound miconazole ear drops (Erkeshu), which are suspensions.
[0221] In addition, the centrifugal stability of the compound gel ear drops of the present application and the commercially available products (Erkeshu compound miconazole ear drops, Aurizon Mafo Micro-Su ear drops, Yierjing compound nystatin ointment, compound ketoconazole ointment) was measured. Take about 10 mL (or g) of each product in a centrifuge tube and centrifuge at 2500 r / min for 30 min. Figure 8 As shown in A in the figure, after centrifugation, it can be seen that the ear drops of the present invention are uniform and not stratified, and the appearance and shape have no obvious change compared with the initial appearance. However, after centrifugation under the above conditions, various commercial products will show different degrees of stratification ( Figure 8 B in the figure), which indicates that the compound ear drops provided in the present application are more stable than commercially available products (a: Erkeshu compound miconazole ear drops; b: Aurizon Mafo micro-su ear drops; c: Yierjing compound nystatin ointment; d: compound ketoconazole ointment; e: the compound gel ear drops of the present invention).
[0222] Example 17 Viscosity and fluidity of the compound gel ear drops of the present application
[0223] Most of the existing compound prescriptions in China are ointments, and ear ointments have low fluidity and do not cover the deep part and surface of the ear canal of dogs and cats evenly, which results in poor efficacy of the drug. Fig. 9 A in the figure is the viscosity curve of the compound gel ear drops stored for 0 days in the accelerated stability test. Fig. 9 B in the figure is the viscosity curve of the compound gel ear drops stored for 6 months in the accelerated stability test. Fig. 9 C Viscosity curve of the commercially available compound miconazole ear drops (Erkeshu). As can be seen from the figure, the viscosity of the compound gel ear drops is moderate, with good viscosity, fluidity and elasticity, and there is almost no difference in viscosity after storage for 6 months, which once again shows that the compound of the application is stable and the quality is controllable.
[0224] Example 18 Comparison of pH values of the compound gel ear drops of the present application and commercially available products
[0225] The pH values of commercially available products and the present invention are shown in Table 21, among which the pH value (6.43) of the compound gel ear drops of the present application is closest to the physiological pH value (6.1) of the pet ear canal. Undoubtedly, in practical application, the ear drops of the present application are less irritating to sick dogs and cats, and have more advantages in compliance than commercially available products.
[0226] Table 21. pH values of commercially available products and this compound
[0227]
[0228] Example 19 Investigation of the skin irritation of the compound gel ear drops
[0229] According to the technical guidelines for drug irritation and allergy research, a rabbit external auditory canal irritation experiment was conducted on Group 8 after storage for 180 days under accelerated conditions (30°C) in Example 8 to observe whether single and multiple drug exposures in the external auditory canal produce irritation reactions at the medication site.
[0230] Four ordinary-grade, 2-month-old male Chinese white rabbits weighing between 2.0 and 2.5 kg were selected and housed in cages. They were fed pelleted feed and had free access to drinking water. The experiment could begin after about one week of acclimatization.
[0231] Chinese white rabbits weighing 2.0-2.5 kg were randomly divided into a single irritation test group and a multiple irritation test group, with 2 rabbits in each group (numbered 1 and 2, left ear is Left, right ear is Right). The left ear was used for medication (patented compound gel ear drops), and the right ear was used for saline as a control. 0.4 mL / time, once a day, for a total of 14 days. When dripping the medicine, grab the rabbit's ear, drip it deep, and rub it briefly with your hands. Observe the skin condition of the rabbit before and after the use of the ear drops, and take photos to record.
[0232] The single irritation test is to remove the test substance 4 hours after application and clean the application site with warm water, and observe the external auditory canal for congestion, edema, redness, swelling, itching, etc. under natural light or full-spectrum light at 1, 24, 48, and 72 hours after cleaning the Ear Clear Ear Drops. The skin irritation reaction score is calculated according to Table 22, and the average score of the test animals is used for comprehensive evaluation. The skin irritation intensity is determined according to Table 23 based on the average of the highest scores at each observation time point of 24, 48, and 72 hours.
[0233] The multiple irritation test was 0.4 mL / time, once / day, and applied continuously for 14 days. The results were observed 1 hour after each treatment. The scores were scored according to Table 22, and finally the average score of each rabbit per day was calculated according to the formula below to determine the skin irritation intensity.
[0234] The irritation results of the compound ear drops of this application are as follows Fig.10As shown, in a single stimulation ( Fig.10 A) and multiple stimulation ( Fig.10 B) No symptoms such as redness, swelling and erythema were observed in the test, indicating that the compound ear drops of the present invention have less irritation to the ear skin, and are expected to have no significant irritation to sick dogs and cats, and have strong compliance.
[0235] Table 22. Skin irritation reaction scores
[0236]
[0237] Table 23. Skin irritation intensity classification
[0238]
[0239] Example 20 Safety Study of Compound Gel Ear Drops
[0240] To ensure the safety of the compound ear drops, a safety study was conducted on Group 8 after storage for 180 days under accelerated (30°C) conditions in Example 8. The patented compound gel ear drops were subjected to a toxicity test in the external auditory canal of rabbits to determine the safe drug concentration and provide a reference for the safety of clinical medication. Ten ordinary-grade, 2-month-old male Chinese white rabbits weighing between 2.0 and 2.5 kg were selected, evenly divided into cages, fed with pelleted feed, and free to drink water. The experiment began after acclimatization for 1 week.
[0241] Chinese white rabbits weighing 2.0-2.5 kg were divided into experimental group, recovery group and control group, including 4 rabbits in the experimental group, 4 rabbits in the recovery group and 2 rabbits in the control group. The left ear of the experimental group and the recovery group was given 5 times the recommended dose, and the control group was given an equal amount of normal saline, 2 mL / time, once a day, for 14 days. After 14 days, blood was collected from the ear vein of the experimental group, the control group and the recovery group after 7 days of stopping the drug administration. 0.5 mL of blood was added to the EDTA anticoagulant tube for blood routine test, and another 1 mL of blood was taken and left to stand at room temperature for 20-30 min, centrifuged at 2000-3000 rpm for 10 min, and the upper serum was separated for the detection of blood biochemical indicators such as liver function (serum alanine aminotransferase ALT, serum aspartate aminotransferase AST, etc.), renal function (urea UREA, creatinine CREA). The liver, kidney and ear tissues of the rabbits were fixed in 4% paraformaldehyde and stained with HE to observe histological changes.
[0242] As attached Fig.11As shown in the figure, the serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST) liver function indexes and renal function indexes such as urea (UREA) and creatinine (CREA) of rabbits in the control group and the recovery group did not change significantly after continuous administration for 14 days, and there was no significant effect on the number of red blood cells (RBC), white blood cells (WBC) and platelets (PLT). Fig.12 As shown in the results, no abnormal changes were found in the ears, liver, kidneys and other tissues of the rabbits. Therefore, after being stored under accelerated conditions (30°C) for 180 days, the compound was administered continuously for 14 days at 5 times the recommended dose without affecting the basic physiological state, liver function and kidney function of the rabbits. It is expected to have good safety for sick dogs and cats.
[0243] Example 21 Therapeutic effect of compound gel ear drops on the rabbit external auditory canal mixed infection model with drug-resistant bacteria
[0244] Establishment of a mixed bacterial and fungal infection model of the external auditory canal
[0245] The experiment was conducted using the compound gel ear drops stored for 180 days under accelerated conditions (30° C.) according to Group 8 in Example 8 above.
[0246] 2-2.5 kg male Chinese white rabbits were selected and evenly divided into cages for feeding. They were fed with pellet feed and had free access to water. The experiment could be started after acclimating to the environment for about one week. Before the experiment, each rabbit was anesthetized by intraperitoneal injection of 100 μL of 1% sodium pentobarbital. The skin of the left ear of the rabbit was cut with an 8 mm corneal trephine. 50 μL of Staphylococcus pseudintermedius (strain number 22022, MIC value of marbofloxacin>8 μg / mL) and Malassezia pachydermatis (strain number CAUF110, MIC value of ketoconazole 2 μg / mL) were dripped into the wound of the rabbit skin using a pipette (the concentration of bacterial solution was ~6× 109 CFU / mL and ~6× 108 CFU / mL, respectively). The wound was sealed with pressure-sensitive tape to prevent the rabbit from scratching the wound, and the rabbit was placed in a cage. 24 hours after the bacterial treatment, the infected rabbits were treated with the recommended dose and course of the compound and commercial products, respectively.
[0247] The rabbit status and ear infection were observed and recorded every 24 h after infection. On the 7th day of treatment, the ear wound tissue was ground, and the grinding solution was diluted 10 times with PBS and spread on the identification medium. After 24 h in the incubator, the number of colonies on the plate was counted.
[0248] Test results
[0249] Within 7 days after infection, the ear status of rabbits in the infection group, the compound gel ear drops treatment group, and the commercial product treatment group was as follows: Fig.13As shown, the results prove that the compound gel ear drops provided by the present application and the commercially available product Aurizon Mafo Micro-Sugar ear drops can effectively reduce the degree of mixed infection in rabbit ears and alleviate the symptoms of infection. The wound of the compound gel ear drops provided by the present application has begun to scab and heal on the 4th day of medication, while the Aurizon group can still see suppuration on the 4th day and even at the end of treatment, and on the 7th day, the wound of the compound gel ear drops group is significantly smaller than that of the Aurizon group ( Fig.13 ).like Fig.14 As shown, the bacterial load of the rabbit ear wound in the compound group was significantly reduced compared with that in the infection group, and the decrease was significantly higher than that in the Aurizon group. In conclusion, the compound gel ear drops provided by the present invention have excellent therapeutic effects on mixed infections of drug-resistant Staphylococcus pseudintermedius and Malassezia pachydermatis, and their effects are significantly better than the commercially available product Aurizon Mafo Micro-Sugar Ear Drops.
[0250] Example 22 Clinical therapeutic effect of compound gel ear drops on infected dogs
[0251] To ensure the effectiveness of the compound ear drops, a clinical treatment trial was conducted on Group 8 after being stored for 180 days under accelerated (30°C) conditions in Example 8. First, the ears of dogs with clinical symptoms of otitis externa such as redness, erosion, and exudate were sampled, and a total of 19 ears with infectious otitis externa were diagnosed by microscopic examination. The compound gel ear drops were used for treatment, and the specific treatment plan was as follows: for ears with fungal infections such as Malassezia detected under the microscope, the compound gel ear drops were used once a day after cleaning the ears, 4-6 drops each time, and used continuously for 14 days; for ears with bacterial infections detected, the compound gel ear drops were used once a day after cleaning the ears, 4-6 drops each time, and used continuously for 7 days. After the end of the medication, the ears were sampled, the changes in the amount of bacteria under the microscope were observed, and recurrence monitoring was performed one week after the medication was stopped. The symptoms of the affected ears were scored by Table 24 to evaluate the therapeutic effect.
[0252] Table 24. Evaluation indicators of otitis externa treatment
[0253]
[0254] In this evaluation scheme, the initial score of the affected ear ≥ 5 points is considered to have clinical symptoms of otitis externa. If the follow-up score is reduced by more than 5 points compared with the initial score, the clinical symptoms of the affected ear are considered to have significantly improved; if the follow-up score is reduced by less than 5 points compared with the initial score, the affected ear is considered to have slightly improved; if the follow-up score is not reduced compared with the initial score, it is considered to have no improvement.
[0255] The clinical scores of the 19 affected ears were statistically analyzed as follows: Fig.15 The scoring results before and after treatment are shown in Table 25. The average score before treatment was 9.74, and the average score after treatment was 2.11. The ear appearance and score were significantly improved before and after treatment ( Fig.16 ). The results showed that after the end of the treatment course, the significant improvement rate of the 19 ears treated reached 89.5% (17 / 19), and the overall effective rate reached 94.7% (18 / 19) (Table 26), indicating that the ear drops provided in this application have excellent therapeutic effects on canine otitis externa in clinical practice. In addition, during the treatment process, pet owners responded that the compound gel ear drops had no irritating odor, good fluidity, and were easy to operate. Although a few dogs occasionally had erythema in their ears during the treatment, it disappeared one week after stopping the medication, which was suspected to be related to the inflammatory response rather than the irritation of the compound. The affected ears were reexamined one week after stopping the medication. Except for one case that showed no improvement, the remaining 18 cases did not relapse, indicating that the compound of this application has a radical effect on canine otitis externa caused by stubborn fungi / bacteria.
[0256] The results of the above embodiments show that the present application actually provides a compound gel ear drops for pets, which are superior to commercially available products (such as Aurizon) in terms of stability, compliance, and efficacy in treating mixed infections with drug-resistant bacteria, and have good safety and significant clinical treatment effects on sick dogs, reflecting the rationality, superiority and creativity of the formula provided in the present application. The transformation and implementation of the application is expected to have excellent market prospects.
[0257] Table 25. Statistics of the therapeutic effect of this compound on canine otitis externa
[0258]
[0259] Table 26. Overall evaluation of the therapeutic effect of this compound on canine otitis externa
[0260]
[0261] The above embodiments are the most preferred modes of the present invention. Those skilled in the art should understand that the details and forms of the technical solutions of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements are within the protection scope of the present invention.
Claims
1. A veterinary marbofloxacin compound gel ear drops, characterized in that: in, The components of the ear drops are composed of the following components before mixing by mass / volume (g / mL): (1) Marbofloxacin 0.33%; (2) Ketoconazole 0.6%; (3) triamcinolone acetonide 0.02%; (4) Permethrin 0.6%; (5) solubilizer 55.0%; (6) latent solvent 41.6%; (7) Solvent 0.6%; (8) Acidity regulator 0.678%; (9) Complexing agent 0.02%; (10) Thickener 2%; (11) Gel 1.0%; (12) Cross-linking agent 0.09%; (13) Stabilizer 4.0%; Wherein, the solubilizing agent is dimethyl sulfoxide; The latent solvent is 1,2-propylene glycol; The cosolvent is sodium hydroxide; The acidity regulator is lactic acid; The complexing agent is disodium edetate; The viscosity increasing agent is polyvinyl pyrrolidone K30; The gel is type B 934 carbomer; The cross-linking agent is triethanolamine; The stabilizer is preparation water; The pH of the compound ear drops is 6.43; The compound gel ear drops are prepared by the following method: 1) Weigh the cosolvent and complexing agent according to the formula amount, dissolve them in water, add the formula amount of marbofloxacin, stir at room temperature until completely dissolved, and set aside; 2) Weigh the acidity regulator according to the formula, add it dropwise into the solution in 1), stir until it is completely dissolved, and set aside; 3) Weigh dimethyl sulfoxide according to the formula amount, add 1,2-propylene glycol according to the above amount, add ketoconazole, triamcinolone acetonide and permethrin according to the formula amount, stir at room temperature until completely dissolved, and set aside; 4) Add the solution in 2) to the solution in 3) and stir continuously until a clear mixed solution is obtained. Filter the mixture through a membrane under negative pressure to remove impurities and set aside. 5) Weigh the viscosity enhancer, gelling agent and cross-linking agent according to the formula amount, add them to the filtrate prepared in 4), and stir at room temperature overnight until they are completely dissolved to obtain the veterinary marbofloxacin compound gel ear drops.
2. The method for preparing the veterinary Marbofloxacin compound gel ear drops according to claim 1, characterized in that: The method comprises the following steps: 1) Weigh the cosolvent and complexing agent according to the formula amount, dissolve them in water, add the formula amount of marbofloxacin, stir at room temperature until completely dissolved, and set aside; 2) Weigh the acidity regulator according to the formula, add it dropwise into the solution in 1), stir until it is completely dissolved, and set aside; 3) Weigh dimethyl sulfoxide according to the formula amount, add 1,2-propylene glycol according to the formula amount, add ketoconazole, triamcinolone acetonide and permethrin according to the formula amount, stir at room temperature until completely dissolved, and set aside; 4) Add the solution in 2) to the solution in 3) and stir continuously until a clear mixed solution is obtained. Filter the mixture through a membrane under negative pressure to remove impurities and set aside. 5) Weigh the viscosity enhancer, gelling agent and cross-linking agent according to the formula amount, add them to the filtrate prepared in 4), and stir at room temperature overnight until they are completely dissolved to obtain the veterinary marbofloxacin compound gel ear drops.
3. Use of the veterinary marbofloxacin compound gel ear drops according to claim 1 in the preparation of drugs for treating bacterial and fungal infections.
4. The use according to claim 3, characterized in that: The bacteria are specifically one or more of Staphylococcus pseudintermedius, Escherichia coli, and Pseudomonas aeruginosa, the fungus is specifically Malassezia pachydermatis, and the infection is specifically a single or mixed infection of the above pathogens.
